Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
NCT02598219 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 262
Last updated 2026-03-18
Summary
The aim of this trial is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).
Conditions
- Non Endometrioid Carcinoma
- Endometrioid Carcinoma
Interventions
- DRUG
-
Pre-operative SN mapping with radionucleide
1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery. 2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection. 3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available.
- DRUG
-
Intra-operative SN mapping with patent V blue dye
1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient. 2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible. 3. SN are detected by direct visualization of blue colored lymphatics and node
- DRUG
-
Intra-operative SN mapping with indocyanin green
1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient. 2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible 3- SN detection by near-infrared fluorescence imaging
- PROCEDURE
-
Full bilateral laparoscopic lymphadenectomy and Hysterectomy
* Bilateral pelvic lymphadenectomy (intermediate risk endometrioid) * Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid) * Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)
- PROCEDURE
-
Current initial staging protocols
Current French initial staging protocols
Sponsors & Collaborators
-
National Cancer Institute, France
collaborator OTHER_GOV -
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
Canceropôle Nord Ouest
collaborator OTHER -
Centre Oscar Lambret
lead OTHER
Principal Investigators
-
Lucie BRESSON, MD · Centre Oscar Lambret
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2024-10-31
- Completion
- 2027-10-31
Countries
- France
Study Locations
More Related Trials
-
3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
NCT04227249 ·Status: NOT_YET_RECRUITING
-
Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer
NCT01946672 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Recurrence for High Risk Endometrial Cancer Patients
NCT04412902 ·Status: COMPLETED
-
Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO)
NCT03580421 ·Status: COMPLETED ·Phase: NA
-
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT06524583 ·Status: RECRUITING ·Phase: PHASE2
-
Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study
NCT06589414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer
NCT01512810 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events
NCT04294589 ·Status: UNKNOWN
-
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NCT06967961 ·Status: RECRUITING ·Phase: NA
-
Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma
NCT01560026 ·Status: UNKNOWN
-
European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III
NCT04504006 ·Status: RECRUITING
-
Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer
NCT02838381 ·Status: COMPLETED ·Phase: NA
-
Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project
NCT01815879 ·Status: UNKNOWN
-
Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
NCT05005650 ·Status: COMPLETED
-
Long-term Oncologic Outcomes of Robotic Versus Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
NCT05181306 ·Status: COMPLETED
-
Medial Border of Laparoscopic D3 Lymphadenectomy for Right Colon Cancer
NCT04518449 ·Status: WITHDRAWN
-
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
NCT02630654 ·Status: COMPLETED
-
Para Aortic Lymphadenectomy : Always ?
NCT04392895 ·Status: COMPLETED
-
RObotic PArtial Nephrectomy National Study
NCT03292549 ·Status: COMPLETED
-
The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma
NCT01677975 ·Status: UNKNOWN ·Phase: NA
-
Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
NCT05246319 ·Status: COMPLETED
-
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
NCT02817958 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer
NCT02333721 ·Status: UNKNOWN ·Phase: NA
-
Preliminary Study on the Metastatic Rate and Clinical Significance of the Anterior Leaf of Vesicouterine Ligament in Early Stage Cervical Cancer
NCT05904977 ·Status: UNKNOWN
-
Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer
NCT02784028 ·Status: COMPLETED ·Phase: NA